Pricey blockbuster GLP-1s are costing users — and most of the rest of us, too — Harvard Gazette

Pricey blockbuster GLP-1s are costing users — and most of the rest of us, too — Harvard Gazette

Health Pricey blockbuster GLP-1s are costing users — and most of the rest of us, too Health insurers are passing along cost for coverage in form of higher rates across the board, policy researcher says Sy Boles Harvard Staff Writer February 13, 2026 7 min read The popularity of pricey GLP-1 drugs has hit the budgets of users — and just about everyone else. In the U.S., about 12 percent of adults sa…